China
REPORT: Wuhan lab has been conducting research for the Chinese military on animal viruses for 9 years
Researchers at the Wuhan Institute of Virology have been studying viruses in animals, including bats, for the past nine years on behalf of the Chinese military, according to new documents obtained by the Daily Mail. The Chinese military had previously denied allegations linking them to the Wuhan lab.
The nearly decade-old project was created by the government and looked at viruses in animals, attempting to figure out the “dark matter” in biology that spreads them.
The Trump Administration had vocally accused the Wuhan lab of conducting military research throughout the Covid pandemic—one which was consistently denied by the majority of main stream media and Trump opposition.
Lianchao Han defected from the Chinese government and spoke to the Daily Mail about the development.
“Many have been working with Western research institutes for years to steal our know-hows, but China still refuses to share critical information a year after the pandemic has killed over 3 million,” Han said.
State Department weapons expert David Asher said China is likely conducting the research for its military with advanced warfare in mind.
“The Chinese have made it clear they see biotechnology as a big part of the future of hybrid warfare,” Asher said. “The big question is whether their work in these fields is offensive or defensive.”
Read the full article here.
Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.
Foreign Desk News writes:
Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.
“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.
Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.
“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.
The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4
— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023
Foreign Desk News adds:
The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.
-
Economy4 days agoNew York City Mayor Eric Adams Proposes Housing Asylum Seekers in Private Homes
-
Economy5 days agoTexas Gov Abbott aims to eliminate property taxes: ‘we must dream big’
-
Immigration3 days agoBiden Administration to allow 40,000 asylum-seekers per month into US with mobile app
-
International3 days agoSaudi Arabia-Israel Deal Remains Biden’s Win to Lose
